Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All News Releases
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Hamburger menu
    • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • Create a Free Account
      • ALL CONTACT INFO
      • Contact Us


        11AM ET Sunday – 8PM ET Friday

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Why PRWeb
    • Contact
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cardiovascular Disease: Recent Drug Advances and Impending Risks


      News provided by

      Research Advisor at Reportbuyer.com

      Oct 14, 2013, 08:30 ET

      Share this article

      Share this article


      London (PRWEB) October 14, 2013 -- There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace.

      Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered.

      This report provides you with a systematic appraisal into the current and future CV market, including...

      A detailed review of the leading brands and how they are being positioned in the market, in addition to the potential impact of generics

      Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established
      Review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered
      Analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested

      Antilipidemics

      The lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) has been shown to reduce the chance of a heart attack and death in people who have an elevated risk of developing heart disease or who already have heart disease. Several drug classes are currently available to treat a range of lipid disorders; each has a different mechanism of action, safety profile and impact on blood lipid profiles to different degrees.

      Key drugs covered by the report include

      Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc...
      Recent generics - Atorvastatin, etc...
      Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc...
      Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr Reddy), etc...
      Long shots - ALN PCS (Alnylam/The Medicine Company), etc...
      Just some of the key questions answered include

      Why are statins the gold stand in lipid lowering therapies and which is the most effective at lowering LDL-C?
      Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market?
      Why are PCSK9 inhibitors important to cardiologists and which drugs are leading the field?
      Kynamro approved in the US but not in Europe… what next?
      What new HDL-C modulating therapies are in development?
      What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma?

      Anticoagulants

      Anticoagulant therapy is the mainstay for the prevention and treatment of thrombotic complications. Doctors commonly give patients anticoagulation therapy during invasive procedures such as angioplasty or coronary stents as well as during elective knee and hip replacement surgery and abdominal surgery where there is an increased risk of blood clots. In addition, patients with an increased risk of thrombosis and/or thromboembolism such as those with acute coronary syndrome (ACS), those suffering with atrial fibrillation (AF; an erratic heart beat) or those with a history of stroke, are often treated with anticoagulant medicines to improve clinical outcomes.

      Key drugs covered by the report include

      Leading brands - Coumadin (Bristol-Myers Squibb), Praxada (Boehringer Ingelheim), Xarelto (Bayer/Johnson & Johnson), etc...
      Recent generics - Clopidogrel, Enoxaparin sodium, etc...
      Ones to watch - Otamixaban (Sanofi), Vorapaxar (Merck & Co.), etc...
      Waiting in the wings - Betrixaban (Portola Pharmaceuticals)
      Long shots - EP217609 (EndotisPharma), etc…
      Just some of the key questions answered include

      Have the new OAPs changed the treatment paradigm for patients at high risk from stroke?
      Will Effient maintain its head start or will the TRIOLOGY ACS trial cause it to stumble?
      What warfarin alternatives have entered the market?
      Boehringer Ingelheim’s Pradaxa is first to the market but what safety issues have been flagged up?
      Why has GlaxoSmithKline's Arixtra failed to impress?
      What new anticoagulant drug classes are in development and who is leading the field?

      Antihypertensives

      High blood pressure or hypertension is a highly prevalent cardiovascular risk factor which is associated with an increased risk of heart attack and stroke. The renin-angiotensin-aldosterone system (RAAS) is widely accepted as the key pathway in the regulation of blood pressure and body volume and has been the target for a cocktail of antihypertensive drugs that include angiotensin receptor blockers (ARBs), angiotensin-converting-enzyme (ACE) inhibitors, aldosterone antagonists and more recently the direct renin inhibitors (DRIs).

      Key drugs covered by the report include

      Leading brands - Avapro (Sanofi/Bristol-Myers Squibb), Diovan (Novartis), Edarbi (Takeda), etc...
      Recent generics - Irbesartan, etc...
      Ones to watch - LCZ696 (Novartis), etc...
      Waiting in the wings - DSP-9599 (Dainippon Sumitomo Pharma), etc...
      Long shots - DARA (Retrophin), etc...

      Just some of the key questions answered include

      What impact have generics had on the sale of Avapro?
      Why have Diovan generics been slow off the mark and have pill combinations offered any protection?
      Will Takeda’s Edarbi become the new gold standard in a market dominated by generics?
      Why has Tekturna not lived up to its promise, do direct renin inhibitors have a future?
      What innovative DRIs are in clinical development?
      What new drug classes are next in line to transform the antihypertensive market?

      Scope of the report 1
      Catalyst 1
      About the author 2
      SECT ION 1: ANTILIPIDEMICS 3
      Introduction - where we are now? 3
      What is the gold standard lipid lowering therapy? 4
      Which statin is most effective at lowering LDL-C? 4
      What impact has generic atorvastatin had on Lipitor? 5
      What impact has generic Lipitor had on statin prescriptions? 5
      Will AstraZeneca’s Crestor win the fight for supremacy? 6
      When will generic rosuvastatin reach the market? 6
      Is statin safety really an issue? 7
      Can Livalo differentiation itself from the pack? 7
      Statins - Market forecasts 9
      New drugs on the block 10
      Approach 1: LDL-C reducing therapies: Drug class 1: PSCK9 inhibitors 11
      Can new LDL-C reducing therapies supersede statins? 11
      Why are PC SK9 inhibitors important to cardiologists? 11
      Ones to watch 13
      Alirocumab (Sanofi/Regeneron Pharmaceuticals) 13
      Sanofi’s comprehensive trial program 13
      Corporate strategy 14
      AMG 145 (Amgen) 14
      Amgen’s comprehensive trial program 14
      Corporate strategy 15
      Waiting in the wings 16
      RG 7652 (Roche) 16
      RN-316 (Pfizer) 16
      Long shots 17
      ALN PC S (Alnylam/The Medicine Company) 17
      PCSK9 inhibitors - Market forecasts 18
      Approach 1: LDL-C reducing therapies: Drug class 2: Apo B modulators 20
      Sanofi’s Kynamro approved in the US but not in Europe… what next? 20
      Why have MTP inhibitors established a niche in hoFH patients? 20
      Juxtapid (Aegerion Pharmaceuticals) 20
      Waiting in the wings 22
      Apo B modulators – Market Forecasts 23
      Approach 2: HDL-C modulating therapies: Drug class 3: CETP inhibitors 24
      Is HDL-C elevation a feasible alternative to LDL-C lowering strategies in lipid control? 24
      Does niacin have a future following the withdrawal of Merck’s Tredaptive? 24
      What new HDL-C modulation therapies are in development? 25
      Can the new CEPT inhibitors succeed where others have failed? 25
      Ones to watch 27
      Anacetrapid (Merck) 27
      Evacetrapid (Eli Lilly) 28
      Waiting in the wings 29
      DRL-17822 (Dr Reddy) 29
      BAY 60–5521 (Bayer Healthcare AG) 29
      BMS-795311 (Bristol-Myers Squibb/Simcere Pharmaceutical Group) 29
      DEZ-001 (Dezima Pharma) 29
      Long shots 30
      ATH03 (AFF iRiS AG) 30
      CETP inhibitors - Market forecasts 31
      Approach 2: HDL-C modulating therapies: Drug class 4: Apo A-1 mimetics 32
      Are apoliproprotein A-I enhancing agents commercially viable? 32
      Ones to watch 33
      RVX-208 (Resverlogix) 33
      Waiting in the wings 34
      Reverse D-4F (Abbott/Arisaph Pharmaceuticals) 34
      Apo A-1 enhancing compounds, what the future holds (market forecasts) 35
      Antilipidemics overall conclusions 36
      SECT ION 2: ANTICO AGULANTS 38
      Introduction – where we are now 38
      Oral anticoagulant agents 39
      Which warfarin alternatives have entered the market? 39
      To bleed or not to bleed that is the question? 40
      Boehringer Ingelheim’s Pradaxa is first to market… 40
      … but safety issues have been flagged up? 41
      When will BI seek approval for Pradaxa in the long-term prevention of recurrent VTEs? 41
      Xarelto is second to market … 41
      …but Bayer’s expectations are high 41
      Why has Xarelto had a mixed response from regulators in ACS patients? 42
      EXPLORER program underway to fuel future growth 42
      Pfizer/BMS Eliquis potentially has a “best in class” profile 43
      Seeking to file for new indication by end of 2013 43
      Can Daiichi-Sankyo’s Lixiana gain a foothold in the oral factor Xa market 43
      Oral anticoagulants – Market forecasts 44
      Parenteral anticoagulants 45
      Lovenox biosimilars are encroaching on the market 45
      Why has GSK’s Arixtra failed to impress? 45
      Parenteral anticoagulants - Market forecasts 46
      Oral antiplatelet agents 47
      Have the new OAPs changed the treatment paradigm for patients at high risk from stroke? 48
      Will Effient maintain its head start or will the TRIOLOGY ACS trial cause it to stumble? 49
      Can AstraZeneca get Brilinta back on track? 49
      Oral antiplatelet agents - Market forecasts 51
      New drugs on the block 52
      Approach 1: Anticoagulant therapies: Drug Class 1: Factor Xa inhibitors 53
      Ones to watch 54
      Otamixaban (Sanofi) 54
      Waiting in the wings 55
      Betrixaban (Portola Pharmaceuticals) 55
      Long shot 56
      EP 217609 (Endotis Pharma) 56
      Factor Xa inhibitors - Market forecasts 57
      Approach 1: Anticoagulant therapies: Drug Class 2: ultra LMWHs 58
      Long shots 59
      Adomiparin (Momenta Pharmaceuticals) 59
      Ultra LMWH - Market forecasts 60
      Approach 2: Antiplatelet therapies: Drug Class 3: P2Y inhibitors 61
      Ones to watch 62
      Cangrelor IV (The Medicine Company) 62
      P2Y inhibitors - Market forecasts 63
      Approach 2: Antiplatelet therapies: Drug Class 4: PAR1 inhibitors 64
      Ones to watch 65
      Vorapaxar (Merck) 65
      PAR1 inhibitors - Market forecasts 66
      Anticoagulant overall conclusions 67
      SECT ION 3: ANTIHYPERTE NSIVES 68
      Introduction – Where we are now 68
      The hypertension market is driven by generics 69
      Avapro’s has witnessed aggressive generic erosion… 69
      But why have Diovan generics been slow off the mark? 70
      Will Takeda’s Edarbi become the new gold standard? 70
      Why has Tekturna not lived up to its promise? 70
      Antihypertensives - Market forecasts 72
      New drugs on the block 73
      Approach 1: RAAS modulators: Drug Class 1: Oral direct renin inhibitor 74
      Waiting in the wings 75
      VTP-27999 (Vitae Pharmaceuticals) 75
      Direct renin inhibitors – Market forecasts 76
      Approach 1: RAAS modulators: Drug Class 2: Dual acting compounds 77
      Ones to watch 78
      LCZ696 (Novartis) 78
      Long shot 79
      DARA (Retrophin) 79
      Dual acting compounds – Market forecasts 80
      Approach 1: RAAS modulators: Drug Class 3: sGC stimulators 81
      Ones to watch 82
      Riociguat (Bayer) 82
      cGS stimulator – Market forecasts 83
      Approach 1: RAAS modulators: Drug Class 4: NRP-A agonist 84
      Long shots 85
      PL-3994 (Palatin Technologies) 85
      NRP-A agonist – Market forecasts 86
      Antihypertensives overall conclusions 87
      Appendix 1 88
      Mechanism of PC SK9 inhibitors 88
      Appendix 2 89
      Alirocumab clinical trial data 89
      Appendix 3 90
      AMG 415 clinical trial data 90
      Appendix 4 92
      Mechanism of CETP inhibition 92
      Appendix 5 93
      Ancetrapid’s clinical trial data 93
      Appendix 6 94
      Evacetrapid clinical trial data 94
      Appendix 7 95
      Mechanism of apoA-1 mimetic 95
      Appendix 8 96
      The coagulation cascade 96
      Appendix 9 97
      Cangrelor IV clinical trial data 97
      Appendix 10 98
      The renin-angiotensin-aldosterone system (RAAS) 98
      Methodology 99
      Primary research 99
      Secondary research 99
      Acronyms 100
      References 102
      ENDNOTE S 106

      List of Tables

      Table 1: Cardiovascular agents by category 1
      Table 2: Lipid-lowering agents, mechanism of action, safety profile and lipid profile 3
      Table 3: Leading statin drugs and combinations 4
      Table 4: Statins on LDL-C reduction and use in moderate to high risk patients with lipid disorders 4
      Table 5: Lipitor’s sales decline, 2010-2012 (sales US$mn) 5
      Table 6: Crestor’s sales being challenged, 2010-2012 (sales US$mn) 6
      Table 7: Statin sales forecast (US$mn), 2011-2017 9
      Table 8: Strategies and targets to modulate LDL-C levels 11
      Table 9: PCSK9 inhibitors in development 11
      Table 10: PCSK9 inhibitor sales forecast (US$mn), 2011-2017 19
      Table 11: Lipid lowering effects of Juxtapid 21
      Table 12: Novel developmental candidates in early stages of development 22
      Table 13: Apo B modulator sales forecast (US$mn), 2011-2017 23
      Table 14: Strategies and targets to modulate HDL-C levels 25
      Table 15: CETP inhibitors in development 26
      Table 16: Potency and efficacy of leading CETP inhibitors, (% change) 27
      Table 17: CETP inhibitor sales forecast (US$mn), 2011-2017 31
      Table 18: Apo A-1 enhancing drugs in development 32
      Table 19: Apo A-I enhancing agent sales forecast (US$mn), 2011-2017 35
      Table 20: Summary of approved and new drugs in development 37
      Table 21: Commonly prescribed anticoagulant agents, mechanism of action and safety profile 38
      Table 22: New oral anticoagulants, approval in patient populations 39
      Table 23: Headline results from Phase III trials of new anticoagulants versus warfarin in AF 40
      Table 24: Oral anticoagulant sales forecast (US$mn), 2011-2017 44
      Table 25: Forecast for leading parenteral anticoagulants (US$mn), 2011-2017 46
      Table 26: Oral anticoagulants potential patient populations 50
      Table 27: Leading OAP drug sales forecast (US$mn), 2011-2017 51
      Table 28: Novel factor Xa inhibitors 53
      Table 29: Factor Xa inhibitors sales forecast (US$mn), 2011-2017 57
      Table 30: Novel ultra LMWH 58
      Table 31: Ultra LMWH sales forecast (US$mn), 2011-2017 60
      Table 32: Novel antiplatelet agents in development 61
      Table 33: P2Y inhibitor sales forecast (US$mn), 2011-2017 63
      Table 34: Novel PAR1 inhibitors in development 64
      Table 35: PAR1 inhibitors sales forecast (US$mn), 2011-2017 66
      Table 36: Summary of approved and new drugs in development 67
      Table 37: Commonly prescribed antihypertensive agents, mechanism of action and safety profile 68
      Table 38: Leading ARBs and generic availability 69
      Table 39: Avapro’s sales, 2011-2012 (sales €mn) 69
      Table 40: Diovan sales, 2011-2012 (sales US$mn) 70
      Table 41: Tekturna fixed combinations 71
      Table 42: Leading ARB sales forecasts (US$mn), 2011-2017 72
      Table 43: DRI sales forecast (US$mn), 2011-2017 72
      Table 44: Novel DRIs in clinical development 74
      Table 45: DTI inhibitors sales forecast (US$mn), 2012-2017 76
      Table 46: Novel dual acting compounds in clinical development 77
      Table 47: Dual acting compounds sales forecast (US$mn), 2012-2017 80
      Table 48: sGC stimulators sales forecast (US$mn), 2011-2017 83
      Table 49: NRP-A agonist sales forecast, 2011-2017 86
      Table 50: Summary of approved and new antihypertensive drugs in development 87
      Table 51: Summary of DFI11565 trial data in primary hypercholesterolemia patients at 12 weeks 89
      Table 52: Summary of trial data in heFH patients at 12 weeks 89
      Table 53: Summary of LAPLACE-TIMI 57 data in 631 primary hypercholesterolemia patients at 12 weeks 90
      Table 54: Summary of MENDEL data in primary hypercholesterolemia at 12 weeks 90
      Table 55: Summary of RUTHERFORD data in heFH patients at 12 weeks 90
      Table 56: Summary of GUASS data in patients intolerant to statins at 12 weeks 91
      Table 57: Summary of anacetrapid monotherapy data (change from baseline) at 24 weeks 93
      Table 58: Summary of evacetrapid monotherapy data (change from baseline) at 24 weeks 94
      Table 59: Summary of evacetrapid combination data (change from baseline) at 24 weeks 94
      List of Charts

      Figure 1: Medicines under development of heart disease and stroke 10
      Figure 2: Sanofi/Regeneron’s comprehensive alirocumab Phase III program 13
      Figure 3: Amgen’s comprehensive AMG 145 Phase III program 15
      Figure 4: Xarelto’s EXPLORER program 42
      Figure 5: Oral antiplatelet market by region, 2012 47
      Figure 6: Oral antiplatelet market by volume, 2012 47
      Figure 7: Oral antiplatelet market, market share of leading agents in leading markets, 2012 48
      Figure 8: Medicines under development of heart disease and stroke 52
      Figure 9: Medicines under development of heart disease and stroke 73
      Figure 10: Schematic mechanism of action of PCSK9 in the liver 88
      Figure 11: Schematic mechanism of action of CETP inhibitors 92
      Figure 12: Schematic mechanism of action of Apo A-1 enhancing agents 95
      Figure 13: Schematic of clotting cascade and site of action of approved anticoagulant drugs 96
      Figure 14: Schematic of the renin-angiotensin-aldosterone system 98

      Read the full report:

      Cardiovascular Disease: Recent Drug Advances and Impending Risks

      http://www.reportbuyer.com/pharma_healthcare/therapeutic/cardiovascular_disease_recent_drug_advances_impending_risks.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

      For more information:
      Sarah Smith
      Research Advisor at Reportbuyer.com
      Email: [email protected]
      Tel: +44 208 816 85 48
      Website: http://www.reportbuyer.com/

      Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]

      Modal title

      Contact PRWeb

      • 11AM ET Sunday – 8PM ET Friday
      • Contact Us

      About PRWeb

      • About PRWeb
      • Partners
      • Partnership Programs
      • Editorial Guidelines
      • Resources

      Why PRWeb

      • Why PRWeb
      • How It Works
      • Who Uses It
      • Pricing

      Accounts

      • Create a Free Account
      • Log in
      • Contact Us

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Online Member Center
      • ProfNet
      Cision Distribution Helpline
      888-776-0942
      • Legal
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 Cision US Inc.